TransGenic Group

TransGenic Group EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of TransGenic Group (2342.T) as of Nov 13, 2026 is 194.82. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 54.34 — a change of 258.50% (higher).

EV/OCF

194.82

YoY

258.50%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of TransGenic Group is 2026 194.82 . EV/OCF (Enterprise Value to Operating Cash Flow) of TransGenic Group was 2025 54.34 . It decreases by 258.50% higher compared to the previous year.

The TransGenic Group EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2019
30.41 JPY
Jan 1, 2020
-243.84 JPY
Jan 1, 2021
3.37 JPY
Jan 1, 2022
1.30 JPY
Jan 1, 2023
-2.84 JPY
Jan 1, 2024
-12.41 JPY
Jan 1, 2025
54.34 JPY
Jan 1, 2026
194.82 JPY
The TransGenic Group EV/OCF history
YEAREV/OCFYoY
194.82+258.50%
54.34-537.85%
-12.41+336.96%
-2.84-317.79%
1.30-61.30%
3.37-101.38%
-243.84-901.74%
30.41+55.91%
19.51+6.10%
18.39-10.01%
20.43-50.67%
41.42-238.21%
-29.97—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TransGenic Group Stock analysis

What does TransGenic Group do? TransGenic Group Inc. generates revenue through three business segments. The Contract Research Organization (CRO) segment provides contract clinical tests for pharmaceuticals and foods, including pharmacodynamic and safety pharmacology tests, as well as non-clinical safety tests for pesticides and food. It also offers contract production of genetically modified mice and antibodies, sales of model mice, and development of new biomarkers. The Diagnostic Analysis segment delivers pathological diagnosis services, gene analysis contract services, and drug discovery support for individualized medicine. The TGBS segment provides business succession and revitalization advice and support services, alongside an electronic commerce (EC) business for retail and wholesale of electrical products. The CRO segment serves pharmaceutical and food companies requiring clinical and non-clinical testing services. The Diagnostic Analysis segment targets healthcare providers and researchers needing diagnostic and drug discovery support. The TGBS segment caters to businesses seeking succession planning and revitalization services, while its EC business sells electrical products to retail and wholesale customers. Revenue streams include fees from clinical and safety testing, production of genetically modified animals, sales of model mice, and development of biomarkers under the CRO segment. The Diagnostic Analysis segment earns from pathology services, gene analysis, and drug discovery support. The TGBS segment generates income through advisory services and EC sales of electrical products. TransGenic Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TransGenic Group stock

EV/OCF (Enterprise Value to Operating Cash Flow) of TransGenic Group is 194.82 in 2026.

EV/OCF (Enterprise Value to Operating Cash Flow) of TransGenic Group changed from 54.34 to 194.82, representing a 258.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) TransGenic Group since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s TransGenic Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — TransGenic Group

All Key Metrics — TransGenic Group